NCT00330161View on ClinicalTrials.gov

Vorinostat in Treating Patients With Progressive Metastatic Prostate Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

29

Participants

Timeline

Start Date

March 31, 2006

Primary Completion Date

September 30, 2009

Study Completion Date

May 31, 2011

Conditions
Recurrent Prostate CancerStage IV Prostate Cancer
Interventions
DRUG

vorinostat

Given orally

OTHER

laboratory biomarker analysis

Correlative studies

Trial Locations (1)

48109

University of Michigan, Ann Arbor

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00330161 - Vorinostat in Treating Patients With Progressive Metastatic Prostate Cancer | Biotech Hunter | Biotech Hunter